A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Kangpu Biopharmaceuticals, Ltd.
Start Date
April 18, 2022
End Date
March 13, 2027
Administered By
Duke Cancer Institute
Awarded By
Kangpu Biopharmaceuticals, Ltd.
Start Date
April 18, 2022
End Date
March 13, 2027